AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23141686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NPWT treatment).
Number of subjects: 6
Study 21233260 — intervention group
Group type: EXPERIMENTAL
Intervention: EVADO
Number of subjects: 165
Study 18928904 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (walking on a treadmill for 60 min)
Number of subjects: 80
Study 18928904 — intervention group
Group type: COMPARATOR
Intervention: Rest (control condition)
Number of subjects: 80
Study 16437736 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical acupuncture (EA) at acupoint BL15, 2 Hz for 10 minutes
Number of subjects: 10
Study 16437736 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical acupuncture (control group)
Number of subjects: 10
Study 12646779 — intervention group
Group type: EXPERIMENTAL
Intervention: Elongated cannula placed in the aorta descendens
Number of subjects: 60
Study 12646779 — intervention group
Group type: COMPARATOR
Intervention: Short aorta ascendens cannula
Number of subjects: 60
Study 11120549 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate (5.6 g/day)
Number of subjects: 52
Study 11120549 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (6.2 g/day)
Number of subjects: 52
Study 9343128 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk centred coordinates
Number of subjects: 6
Study 9343128 — intervention group
Group type: EXPERIMENTAL
Intervention: Single word reading task with stimuli presented to the right of the body's midline
Number of subjects: 6
Study 9343128 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 6
Study 8421037 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone scintigraphy management
Number of subjects: 160
Study 8421037 — intervention group
Group type: COMPARATOR
Intervention: Positive radiographs treatment (cast for 12 weeks)
Number of subjects: 160
Study 3891284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide 0.5 micrograms/kg
Number of subjects: 82
Study 3891284 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 0.5 mg/kg
Number of subjects: 82
Study 30656404 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 µg/kg/hr for 1 hour, followed by 0.2 µg/kg/hr)
Number of subjects: 47
Study 30656404 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control group)
Number of subjects: 47
Study 29973211 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based commercial weight loss programme (CP)
Number of subjects: 467
Study 29973211 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 467
Study 29973211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 467
Study 27632856 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body-Vibration (WBV) training combined with trunk-muscle training for 8 weeks
Number of subjects: 20
Study 27632856 — intervention group
Group type: COMPARATOR
Intervention: Non-WBV group performing the same muscle-training program without WBV for 8 weeks
Number of subjects: 20
Study 25407009 — intervention group
Group type: EXPERIMENTAL
Intervention: Group schema therapy (GST)
Number of subjects: 448
Study 25407009 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 448
Study 25276703 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lavender scent 30 minutes before IUD insertion
Number of subjects: 106
Study 25276703 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation 30 minutes before IUD insertion
Number of subjects: 106
Study 25276703 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lavender scent
Number of subjects: 106
Study 20878048 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (n = 11)
Number of subjects: 25
Study 20878048 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 25
Study 18628435 — intervention group
Group type: EXPERIMENTAL
Intervention: F&V diet (high in selected citrus fruit, crucifers, and soy)
Number of subjects: 63
Study 18628435 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (devoid of fruits, vegetables, and soy)
Number of subjects: 63
Study 18628435 — intervention group
Group type: EXPERIMENTAL
Intervention: F&V diet
Number of subjects: 63
Study 16104966 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC (scaled with Gracey curettes)
Number of subjects: 40
Study 16104966 — intervention group
Group type: EXPERIMENTAL
Intervention: CIUS (scaled with ultrasonic device)
Number of subjects: 40
Study 16104966 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC (calculus deattachment with Gracey curettes and brushing with saline solution)
Number of subjects: 40
Study 16104966 — intervention group
Group type: EXPERIMENTAL
Intervention: CDUS (calculus deattachment with ultrasonic device and brushing with saline solution)
Number of subjects: 40
Study 11818641 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab plus low-dose heparin
Number of subjects: 107
Study 11818641 — intervention group
Group type: COMPARATOR
Intervention: standard-dose heparin
Number of subjects: 107
Study 10362368 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target INR 2.0 to 2.5) and Aspirin (150 mg) daily
Number of subjects: 43
Study 10362368 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (150 mg) alone
Number of subjects: 43
Study 10362368 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline culprit artery CTFC
Number of subjects: 43
Study 7572757 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor (EGF) mouthwash
Number of subjects: 12
Study 7572757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2344298 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol (700 mg/day of egg yolk cholesterol)
Number of subjects: 56
Study 7149451 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) consisting of breathing through an inspiratory resistance (IR) for 15 min twice daily for 4 weeks
Number of subjects: 11
Study 7149451 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 11
Study 7149451 — intervention group
Group type: COMPARATOR
Intervention: Control period (4 weeks without IMT)
Number of subjects: 11
Study 31990759 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 15
Study 31990759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30943832 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 29892
Study 30943832 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 29892
Study 30943832 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 29892
Study 30943832 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 29892
Study 28408020 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP‐SHOCK II risk score (derived from six independent predictors)
Number of subjects: 137
Study 28408020 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP‐SHOCK II risk score (external validation in CardShock trial)
Number of subjects: 137
Study 28408020 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP‐SHOCK II risk score (Kaplan-Meier analysis)
Number of subjects: 137
Study 26238707 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir 600 mg once daily with peginterferon-α2a and ribavirin (PR)
Number of subjects: 1081
Study 26238707 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir 400 mg twice daily with peginterferon-α2a and ribavirin (PR)
Number of subjects: 1081
Study 26238707 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon-α2a and ribavirin (PR) alone
Number of subjects: 1081
Study 26238707 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisporivir/PR
Number of subjects: 1081
Study 24332123 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-5ARI (discontinue 5α-reductase inhibitor)
Number of subjects: 230
Study 24332123 — intervention group
Group type: COMPARATOR
Intervention: DC-α-blocker (discontinue α-blocker)
Number of subjects: 230
Study 24332123 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-5ARI
Number of subjects: 230
Study 24332123 — intervention group
Group type: COMPARATOR
Intervention: DC-α-blocker
Number of subjects: 230
Study 22989086 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (16 weeks)
Number of subjects: 30
Study 22989086 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 30
Study 19028052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood (4 degrees C blood)
Number of subjects: 172
Study 19028052 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid (4 degrees C lactated Ringer's solution)
Number of subjects: 172
Study 17296194 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingography (HSG) followed by laparoscopy
Number of subjects: 178
Study 17296194 — intervention group
Group type: COMPARATOR
Intervention: Immediate laparoscopy
Number of subjects: 178
Study 15482084 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery-induced craving (imagined a scene describing smoking urges)
Number of subjects: 40
Study 15482084 — intervention group
Group type: COMPARATOR
Intervention: Rest (control group)
Number of subjects: 40
Study 15482084 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measurement of TCQ
Number of subjects: 40
Study 11561388 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational feedback
Number of subjects: 103
Study 11561388 — intervention group
Group type: EXPERIMENTAL
Intervention: Task feedback
Number of subjects: 103
Study 11561388 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation and task feedback
Number of subjects: 103
Study 11561388 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 103
Study 11561388 — intervention group
Group type: EXPERIMENTAL
Intervention: All feedback types
Number of subjects: 103
Study 9626838 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-1 infusion
Number of subjects: 10
Study 7933325 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent split‐antigen vaccine containing A/Beijing/352/89 (H3N2) and B/Bangkok/163/90 (B/Panama/45/90‐like strain)
Number of subjects: 137
Study 7933325 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 137
Study 3261766 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of phenol (5%) in arachis oil with bulk laxative (Group 1)
Number of subjects: 43
Study 3261766 — intervention group
Group type: COMPARATOR
Intervention: Bulk laxative alone (Group 2)
Number of subjects: 43
Study 30231640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-evolution opinion paired with a male celebrity
Number of subjects: 0
Study 30231640 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-evolution opinion paired with a male celebrity
Number of subjects: 0
Study 30231640 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral opinion paired with a male celebrity
Number of subjects: 0
Study 30231640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-evolution opinion paired with a female celebrity
Number of subjects: 0
Study 30231640 — intervention group
Group type: COMPARATOR
Intervention: Pro-evolution opinion paired with a male expert
Number of subjects: 0
Study 26857949 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (10 mg over 1 hour)
Number of subjects: 28
Study 26857949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nebulized saline)
Number of subjects: 28
Study 25659589 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based peer support intervention
Number of subjects: 192
Study 23761482 — intervention group
Group type: EXPERIMENTAL
Intervention: S (100% soybean oil)
Number of subjects: 144
Study 23761482 — intervention group
Group type: EXPERIMENTAL
Intervention: MS (50% medium‐chain triglycerides and 50% soybean oil)
Number of subjects: 144
Study 23761482 — intervention group
Group type: EXPERIMENTAL
Intervention: MSF (50% medium‐chain triglycerides, 40% soybean oil, and 10% fish oil)
Number of subjects: 144
Study 23761482 — intervention group
Group type: EXPERIMENTAL
Intervention: OS (80% olive oil and 20% soybean oil)
Number of subjects: 144
Study 23761482 — intervention group
Group type: EXPERIMENTAL
Intervention: MOSF (30% medium‐chain triglycerides, 25% olive oil, 30% soybean oil, and 15% fish oil)
Number of subjects: 144
Study 21223712 — intervention group
Group type: EXPERIMENTAL
Intervention: CTOP
Number of subjects: 196
Study 21223712 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 196
Study 18371487 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha (1.5 microg/kg every 20 days for 3 months) plus oral iron
Number of subjects: 32
Study 18371487 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus oral iron
Number of subjects: 32
Study 16817918 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide 10 mg t.d.s.
Number of subjects: 1637
Study 16817918 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg t.d.s.
Number of subjects: 1637
Study 16817918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of hyoscine and paracetamol
Number of subjects: 1637
Study 16817918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1637
Study 15013050 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA 125 mg per day
Number of subjects: 0
Study 15013050 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA 250 mg per day
Number of subjects: 0
Study 15013050 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA 375 mg per day
Number of subjects: 0
Study 15013050 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA 500 mg per day
Number of subjects: 0
Study 15013050 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA (all doses)
Number of subjects: 0
Study 10962418 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (500,000 KIU)
Number of subjects: 13
Study 10962418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9066324 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil diluted with dextrose (10 micrograms)
Number of subjects: 40
Study 9066324 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal sufentanil diluted with normal saline (10 micrograms)
Number of subjects: 40
Study 8092794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasonography
Number of subjects: 0
Study 8092794 — intervention group
Group type: COMPARATOR
Intervention: Preoperative ultrasonography
Number of subjects: 0
Study 8092794 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative palpation
Number of subjects: 0
Study 8092794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative exploration (palpation or ultrasound, or both)
Number of subjects: 0
Study 3012808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam (1 gram) and ampicillin (2 grams) every six hours
Number of subjects: 60
Study 3012808 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (600 mg) every six hours and tobramycin (1.5 mg/kg) every eight hours
Number of subjects: 60
Study 3012808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam and ampicillin
Number of subjects: 60
Study 3012808 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and tobramycin
Number of subjects: 60
Study 31871045 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 43
Study 29059417 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Talk About Smoking (interactive web-based motivational tool)
Number of subjects: 81
Study 29059417 — intervention group
Group type: COMPARATOR
Intervention: Standard education (computerized standard education from the National Cancer Institute)
Number of subjects: 81
Study 29059417 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic comparison condition (minimal tobacco assessment at baseline, no intervention)
Number of subjects: 81
Study 27922760 — intervention group
Group type: EXPERIMENTAL
Intervention: NerveCheck (quantitative sensory testing device)
Number of subjects: 144
Study 23568039 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal surgery
Number of subjects: 38
Study 23568039 — intervention group
Group type: COMPARATOR
Intervention: Control group (43 healthy volunteers)
Number of subjects: 38
Study 23328235 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) with computed tomographic (CT) guidance in Group A (19 patients)
Number of subjects: 32
Study 23328235 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment for metastatic lymph nodes in Group B (13 patients)
Number of subjects: 32
Study 20801120 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of lansoprazole twice daily
Number of subjects: 75
Study 20801120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 18727689 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (AD) + mood stabilizer (MS)
Number of subjects: 350
Study 15537676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (two doses of intravenous ketamine)
Number of subjects: 0
Study 15537676 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 12682003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab (20 mg bolus)
Number of subjects: 403
Study 12682003 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab (20 mg bolus)
Number of subjects: 403
Study 10230256 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral leukocyte count greater than 13,000/mm3
Number of subjects: 181
Study 10230256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural or pulmonary alterations observed on chest X‐ray
Number of subjects: 181
Study 10230256 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral leukocyte count greater than 13,000/mm3 and/or pleural or pulmonary alterations on chest X‐ray
Number of subjects: 181
Study 10230256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranson criteria greater than or equal to three
Number of subjects: 181
Study 10230256 — intervention group
Group type: EXPERIMENTAL
Intervention: Alterations on chest X‐rays
Number of subjects: 181
Study 10230256 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteration of at least one of the abnormal findings on the chest X‐ray and a peripheral leukocyte count greater than 13,000/mm3
Number of subjects: 181
Study 8728459 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude cervical manipulation twice a week for 3 weeks
Number of subjects: 39
Study 8728459 — intervention group
Group type: COMPARATOR
Intervention: Low-level laser in the upper cervical region and deep friction massage in the lower cervical/upper thoracic region, twice a week for 3 weeks
Number of subjects: 39
Study 1925506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin infusion
Number of subjects: 69
Study 1925506 — intervention group
Group type: COMPARATOR
Intervention: Routine control
Number of subjects: 69
Study 6345374 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 8
Study 6345374 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg nifedipine
Number of subjects: 8
Study 6345374 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg nifedipine
Number of subjects: 8
Study 6345374 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of nifedipine (20 mg, 40 mg, 60 mg)
Number of subjects: 8
Study 6345374 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (all doses)
Number of subjects: 8
Study 31556824 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MoI) intervention with initial counseling call and up to 2 monthly follow-up calls by pharmacy students trained in MoI.
Number of subjects: 456
Study 31556824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MoI intervention).
Number of subjects: 456
Study 31556824 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MoI) intervention.
Number of subjects: 456
Study 29336388 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 108
Study 27574437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg once daily (qd) or twice daily (bid)
Number of subjects: 2108
Study 24585720 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX/cetuximab (arm A)
Number of subjects: 111
Study 24585720 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI/cetuximab (arm B)
Number of subjects: 111
Study 24585720 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resection (n = 36)
Number of subjects: 111
Study 24585720 — intervention group
Group type: EXPERIMENTAL
Intervention: No R0 resection
Number of subjects: 111
Study 24585720 — intervention group
Group type: EXPERIMENTAL
Intervention: R0 resection
Number of subjects: 111
Study 22170083 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy 5 × 5 Gy, operated on 7-10 days after irradiation
Number of subjects: 154
Study 22170083 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy 5 × 5 Gy, operated on after 4-5 weeks
Number of subjects: 154
Study 22170083 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy 5 × 5 Gy, patients with downstaging
Number of subjects: 154
Study 22170083 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy 5 × 5 Gy, longer time interval between radiotherapy and surgery
Number of subjects: 154
Study 22170083 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy 5 × 5 Gy
Number of subjects: 154
Study 22170083 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy 5 × 5 Gy, longer time interval
Number of subjects: 154
Study 20645219 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy (STDP)
Number of subjects: 49
Study 20645219 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy (CT)
Number of subjects: 49
Study 17923721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (obesity prevention programme)
Number of subjects: 434
Study 17923721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 434
Study 15303141 — intervention group
Group type: EXPERIMENTAL
Intervention: MBT appliance with en masse retraction
Number of subjects: 37